Schonfeld Strategic Advisors LLC Myovant Sciences Ltd. Transaction History

Schonfeld Strategic Advisors LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$11.6 - $20.44 $601,425 - $1.06 Million	51,847 New	51,847 $930,000
Q4 2021 Feb 14, 2022	SELL	$14.31 - $23.87 $130,221 - $217,217	-9,100 Closed	0 $0
Q3 2021 Nov 16, 2021	SELL	$18.94 - $26.99 $45,456 - $64,775	-2,400 Reduced 20.87%	9,100 $205,000
Q2 2021 Aug 16, 2021	BUY	$17.07 - $24.56 $196,305 - $282,440	11,500 New	11,500 $262,000
Q3 2020 Nov 16, 2020	SELL	$14.05 - $22.6 $184,055 - $296,060	-13,100 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$7.34 - $20.84 $96,154 - $273,004	13,100 New	13,100 $270,000
Q1 2020 May 15, 2020	SELL	$6.55 - $14.76 $392,345 - $884,124	-59,900 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$4.2 - $19.21 $155,820 - $712,691	37,100 Added 162.72%	59,900 $930,000
Q3 2019 Nov 14, 2019	BUY	$5.19 - $9.46 $118,332 - $215,688	22,800 New	22,800 $119,000
Q4 2017 Feb 14, 2018	SELL	$11.37 - $16.4 $760,653 - $1.1 Million	-66,900 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$9.93 - $15.47 $664,317 - $1.03 Million	66,900	66,900 $1.04 Million

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.